Company Overview of VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists f...
1700 Seventh Avenue
Seattle, WA 98101
Founded in 2006
Key Executives for VentiRx Pharmaceuticals, Inc.
Vice President of Finance
Vice President of Business Development & Alliance Management
Compensation as of Fiscal Year 2013.
VentiRx Pharmaceuticals, Inc. Key Developments
VentiRx Pharmaceuticals, Inc. Announces the Completion of Patient Enrollment in Randomized, Placebo-Controlled Phase 2 Trial of VTX-2337
Apr 17 14
VentiRx Pharmaceuticals, Inc. announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. VTX-2337 is a novel, investigational small molecule that targets Toll-like receptor 8 (TLR8). PLD is the standard of care for the treatment of platinum-resistant ovarian cancer and encouraging data have been reported with PLD and VTX-2337 in a recently completed Phase 1b study (GOG-9925, NCT01294293). The Phase 2 GOG-3003 study has reached its target enrollment with more than 290 patients randomized at over 85 institutions throughout North America. The study is being performed in collaboration with the Gynecologic Oncology Group partners program. Women were randomized to receive PLD plus VTX-2337 or PLD plus placebo. The primary endpoint of the trial is overall survival. GOG-3003 is one of two Phase 2 clinical trials of VTX-2337 currently underway. The second trial, called Active8, is a company-sponsored, randomized, Phase 2 placebo-controlled trial in patients with locally advanced and metastatic squamous cell carcinoma of the head and neck. The study is evaluating VTX-2337 in combination with cetuximab and chemotherapy vs. cetuximab and chemotherapy alone. Progression-free survival is the primary endpoint.
Ventirx Pharmaceuticals, Inc. Presents Phase 1 Data on VTX-2337
Feb 20 14
VentiRx Pharmaceuticals, Inc. announced the presentation of clinical data of VTX-2337, a cancer immunotherapy, in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) at the 2014 Multidisciplinary Head and Neck Cancer Symposia in Scottsdale, Arizona. Results indicate that the combination of VTX-2337 and cetuximab is well tolerated with no evidence of synergistic toxicities. Encouraging signs of efficacy provided the rationale for the ongoing randomized placebo controlled Phase 2 study of VTX-2337 in combination with cetuximab, platinum and 5-FU in patients with recurrent or metastatic SCCHN. This trial is actively recruiting patients at approximately 50 clinical sites in the United States. Evidence of the ability of VTX-2337, a Toll-like Receptor 8 (TLR8) agonist, to augment the effect of cetuximab was reported in a Phase 1b investigator initiated trial conducted with the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. The study of twelve patients with advanced SCCHN demonstrated that the combination of VTX-2337 with cetuximab is safe and well tolerated. Serum biomarkers were consistent with TLR8 activation. Ex-vivo analysis of natural killer cells collected pre-dose and twenty four hours after dosing demonstrated increased NK cell mobilization and activation. This supports the proposed mechanism that VTX-2337 augments the effect of cetuximab by activating NK cells and further stimulating ADCC resulting in synergistic anti-tumor activity. All twelve patients were evaluable for tumor response by RECIST 1.1. Two patients (17%) achieved a partial response and 33% of patients had a best response of stable disease.
VentiRx Pharmaceuticals, Inc. Appoints James Kyle Bryan, M.D. as Chief Medical Officer
Apr 23 13
VentiRx Pharmaceuticals, Inc. announced the appointment of James Kyle Bryan, M.D. as Chief Medical Officer. He includes extensive operational and strategic leadership work in his previous roles as Vice President of Global Product Development at PPD, Inc. and as Vice President of Medical Affairs at Seattle Genetics. Board-certified in medical oncology, hematology and internal medicine, Dr. Bryan currently serves on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|